SNY vs VRTX
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
Sanofi presents a mixed profile characterized by a stable Piotroski F-Score of 4/9 and a very conservative debt-to-equity ratio of 0.28. While the stock trades near its Graham Number ($43.22), it is significantly above its growth-based intrinsic value ($16.66), suggesting a valuation premium. The most critical concern is the unsustainable dividend payout ratio of 96.04%, which threatens the long-term viability of the 5.04% yield. Despite a bearish technical trend (0/100), the low forward P/E of 9.09 and positive analyst targets provide a counter-balance to the current stagnation.
VRTX shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
SNY vs VRTX: Head-to-Head Comparison
This page compares Sanofi (SNY) and Vertex Pharmaceuticals Incorporated (VRTX) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.